secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001104659-24-033494
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea raises up to $34M in private placement; FDA clears IND for APR-1051
-------------------------------------------------------------------------

- $16M upfront gross proceeds from private placement; up to $18M additional from warrant exercise.
- Financing led by Sphera Healthcare with Nantahala, DAFNA, Exome, Stonepine, and insiders.
- Shares at $7.29; Tranche A warrants at $7.29 and Tranche B at $9.1125, tied to RP2D milestones.
- FDA cleared IND for APR-1051, a next-gen WEE1 inhibitor for Cyclin E overexpressing cancers.
- Phase 1 ACESOT-1051 trial to start H1 2024; update expected Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465924033494/0001104659-24-033494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465924033494/tm248508d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-033494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer